Priya Vakharia, MD Curriculum Vitae

July 2017-July 2019
Tufts New England Eye Center/Ophthalmic Consultants of Boston Boston, MA
Vitreoretinal surgery fellowship

July 2014- June 2017
Wills Eye Hospital Philadelphia, PA
Ophthalmology residency
Chief Resident 2016-2017

June 2013- June 2014
Lankenau Medical Center Wynnewood, PA
Internal Medicine Internship

July 2009 – May 2013
Jefferson Medical College of Thomas Jefferson University Philadelphia, PA
Doctor of Medicine Degree, May 30, 2013
Summa Cum Laude, Alpha Omega Alpha Honor Society

July 2007-May 2009
The Pennsylvania State University State College, PA
B.S. in General Science, Pennsylvania State Accelerated Medical Program, May 2011
With Highest Distinction (4.0 GPA)

(submission pending) Drying and durability of faricimab in the treatment of neovascular AMD.

(Accepted to Ophthalmology Retina) Fein J, Vakharia PS, Chous AP, et al. Effect of aflibercept 8 mg on anatomic and visual outcomes in nAMD: A post hoc analysis of the Phase 2 CANDELA study.

Sambhara D, Vakharia PS, Eichenbaum DE. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series: BMJ Open Ophthalmology 2025; 10:e002091.

Vakharia PS and Eichenbaum DE. Geographic Atrophy: Current and future therapeutic agents and practical considerations for retinal specialists. Curr Opinion Ophthalmol 2024 May; 35(3): 165-9

Vakharia PS, Eichenbaum DA, Baumal C. Biosimilars in the Treatment of Retinal Disease in the United States. Ophthalmic Surg Lasers Imaging Retina. 2023;54.

Duker J, Vakharia PS, Rifkin L, Duker J, Shah CP. Submacular Choroidal Granuloma from Sarcoidosis: A Case Report. Touch Ophthalmol 2023; 17(1): 42-44.

Member of Post-Injection Endophthalmitis Study Group (acknowledgment). Patel, SN, Tang PH, Storey PP, et al. The influence of universal face mask use on endophthalmitis risk after intravitreal anti-VEGF injections during the COVID-19 pandemic. Ophthalmology 2021. 128(11): 1620-26.

Venincasa, MJ, Sridhar J, Bagheri N, Chao D, Vakharia P. Comment on Sex Differences in the Repair of Retinal Detachments in the United States. Am J Ophthalmol 2020.

Member of Aflibercept Sterile Inflammation Research Group (acknowledgement). Aflibercept-Related Sterile Intraocular Inflammation Outcomes. Ophthalmology Retina 2019.

Storey P, Wolfe J, Inoue M, Obeid A, Todorich B, Pancholy M, Garg S, Hirakata A, Shah A, Okada A, Mirozane Y, Chen E, Prenner J, Tauqeer Z, Borkar D, Abbey A, Jeng-Miller K, Shah S, Pendri P, Yonekawa Y, Sharma P, Wood E, Shah C, Shiraga F, Koto T, Harkey S, Williams P, Hosokawa-Morizane M. The impact of prefilled synringes on endophthalmitis follow intravitreal injection of ranibizumab. Am J Ophthalmol 2019. 199: 200-208.

Chen X, Sharma P, Baumal C. Pigmentary reaction around Gore-Tex suture in a scleral-fixated intraocular lens. Ophthalmology 2018. Epub ahead of print.

McKeague M, Sharma P, Ho AC. Evaluation of the macular prior to cataract surgery. Curr Opin Ophthalmol 2017. Epub ahead of print. PMID 28902720.

Say EA, Samara WA, Khoo CT, Magrath GN, Sharma P, Ferenczy S, Shields CL. Parafoveal capillary density after plaque radiotherapy for choroidal melanoma. Analysis of eyes without radiation maculopathy. Retina 2016; 36(9) 1670-8. PMID 27232466

Sridhar J, Shahlaee A, Sharma P. En face: Disappearing outer retinal dots in treated Syphilitic Chorioretinitis. Ophthalmology 2016; 123(3): 557. PMID 26902563

Sharma P, Sridhar J, Mehta S. Flashes and Floaters. Prim Care 2015; 42(3): 425-35. PMID 26319347

Sharma P, Sridhar J, Rayess N, Maguire J. Optical coherence tomography angiography (OCT-A) of type 2 retinal arteriovenous malformation. Can J Ophthalmol 2015 Oct; 50(5):e93-6. PMID 26455992

Yakopson VS, Carrasco JR, Sharma P, Rabinowitz MP, Stefanyszyn MA. Effect of orbital steroid injections on intraocular pressure. Thyroid Disorders Ther 2015; 1-4.

Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol 2015; 159(5): 861-7. PMID 25660387

Rabinowitz MP, Katz LJ, Moster MR, Myers JS, Pro MJ, Spaeth GL, Sharma P, Stefanyszyn MA. Unilateral prostaglandin-associated periorbitopathy: A syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthal Plast Reconstr Surg 2015; 31(5): 373-8. PMID 25393907

Sharma P, Kaliki S, Pena MS, Shields CL. Choroidal nevus in a child with oculocutaneous albinism. JAAPOS. 2013; 17(2): 203-5. PMID 23352722

Weksler B, Sharma P, Moudgill N, Chojnacki KA, Rosato EL. Robot-assisted minimally invasive esophagectomy is equivalent to thoracoscopic minimally invasive esophagectomy. Dis Esophagus 2012; 25(5): 403-9. PMID: 21899652

Shields CL, Kancherla S, Patel J, Vijayvargiya P, Suriano MM, Kolbus E, Badami A, Sharma P, Jacobs E, Voluck M, Zhang Z, Kansal R, Shields PW, Bianciotto CG, Shields JA. Clinical survey of 3680 iris tumors based on patient age at presentation. Ophthalmology 2012; 119(2): 407-14. PMID 22035581

Sharma P, Shields CL, Turaka K, Eagle RC Jr, Shields JA. Ciliary body medulloepithelioma with neoplastic cyclitic membrane imaging with fluorescein angiography and ultrasound biomicroscopy. Graefes Arch Clin Exp Ophthalmol 2011; 249(8): 1259-61. PMID 21505878

Grove TL, Ahlum JH, Sharma P, Krebs C, Booker SJ. A consensus mechanism for radical SAM-dependent dehydrogenation? BtrN contains two [4Fe-4S] clusters. Biochemistry 2010; 49(18): 3783-5. PMID 20377206

Vakharia PS and Eichenbaum DA. The Landscape of Gene Therapy for Diabetic Retinopathy. Retinal Physician. May 2024. Print.

Vakharia PS. Women in Retina Clinical Trial Incubator. Retina Times. Spring 2024. Print

Vakharia PS and Palma C. Challenging Interpersonal Relationships. Retina Times. Spring 2024. Print

Vakharia PS. Retinal Physician. Anti-complement Therapies for the Treatment of Geographic Atrophy. Retinal Physician Email Newsletter. December 2023

Vakharia PS and Palma C. Tips for Maintaining Workplace Harmony. Retina Times. Spring 2023.

Vakharia PS. Artificial Intelligence for the Screening of Diabetic Retinopathy. Retinal Physician. Nov 2022.

Vakharia PS and Palma C. Managing Sick or Parental Leave. Retina Times. Fall 2022..

Vakharia PS. Clinical Case Compendium. Retina Today. Subretinal Tissue Plasminogen Activator (tPA) for the Management of Submacular Hemorrhage. July/August 2022.

Vakharia PS. Intravitreal methotrexate for the treatment and prevention of proliferative vitreoretinopathy. Retinal Physician. June 2022.

Vakharia PS and Palma C. Managing Your Relationship with Time. Retina Times. Spring 2022.

Vakharia PS. Managing Intraoperative Complications. Spring 2022. Part 2. Retina Times

Vakharia PS. Managing Intraoperative Complications. Winter 2021. Part 1. Retina Times

Vakharia PS. Clinical Case Compendium. Retina Today. July/August 2021. Vitrectomy for Rhegmatogenous Retinal Detachment Secondary to Acute Retinal Necrosis.

Vakharia PS. Clinical Case Compendium. Retina Today. July/August 2021. Bimanual Vitrectomy and Membrane Peeling for Tractional Retinal Detachment from Proliferative Diabetic Retinopathy.

Vakharia PS. Anti-VEGF therapy and AMD. April 2021. Retinal Physician.

Vakharia PS and Palma C. Facing the Tough Lessons of your First Few Years in Practice. Fall 2021.

Vakharia PS and Palma C. How to Handle Difficult Situations with Referring Providers. Retina Times. Spring 2021.

Vakharia PS and Palma C. Mastering the Art of Teaching Fellows to Excel. Retina Times. Fall 2020.

Vakharia PS and Chung M. Retina Peers Offer Advice on the Softer Side of Medicine. Retina Times. Spring 2020.

Sharma P and Shah CP. Update on multimodal imaging for plaquenil toxicity. Retina Today. April 2019.

Sharma P and Heier JS. Update on Phase 3 clinical trial of Conbercept for the treatment of wet age-related macular degeneration. Retinal Physician. April 1, 2019.

Sharma P and Heier JS. Endoscopic Vitrectomy: An adjunctive tool for vitreoretinal surgery. Retina Today. April 2019.

Sharma P, Joseph A. Retinal progenitor cells for the treatment of retinitis pigmentosa. Retina Times. Nov 2018.

Sharma P, Sridhar J, Mehta S. Resident case series, Multiple evanescent white dot syndrome. Review of Ophthalmology. 2015.

Ullman MA, Sharma P, Shields CL. Slow growth of choroidal nevus in a child. Retina Today. April 2013;48-50.

Morton SJ, Sharma P, Shields CL. Strategies in minimizing radiation maculopathy. Retina Today. March 2013;38-40.

Huggins A, Patel J, Melnyk M, Sharma P, Finklea B, Cutler N, Wilson M, Ahmed F, Adam M. Review of “Effect of femtosecond laser-assisted cataract surgery on the corneal endothelium.” Eyeworld Journal Club. November 2014. http://eyeworld.org/article.php?sid=7546

Vakharia P. PFO, gas, and oil complications. ASRS Retina Atlas.

Vakharia P. Ophthalmology Secrets, Chapter 40, Toxic Retinopathies.

Vakharia P and Shah CP. Wet Age-Related Macular Degeneration. The Pocket Guide to Medical Retina. Slack Incorporated. 2021. Print

Vakharia P and Shah CP. Lattice Degeneration. The Pocket Guide to Medical Retina. Slack Incorporated. 2021. Print

Sharma P and Baumal C. Photic Retinopathy. Macular Disorders. Springer Publishing. 2020. Print.

Sharma P and Shah CP. Primary Rhegmatogenous Retinal Detachment. The Retina Illustrated. 2019. Thieme Publishing, Print.

Sharma P, Sridhar J, Regillo CR. Surgical approaches for cell transplantation. Cellular Therapies for Retinal Disease: A Strategic Approach. Springer International Publishing, 2017. Print.

Sharma, P: Contributor. Wills Eye Manual: Seventh Edition. Office and emergency room diagnosis and treatment of eye disease. Lippincott Williams & Wilkins, 2017. Print.

Sharma P, Sergott RC. Guide to OCT interpretation with normals and anatomic variants. Optical Coherence Tomography. Switzerland: Springer International Publishing, 2016. Print.

Sharma, P: Contributor for Tully A and Studdiford JS. USMLE Images for the Boards: A Comprehensive Image-based Review. Philadelphia, PA: Saunders, 2012. Print.

2024 Retina World Congress. Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for Aflibercept 8 mg and 2 mg and Association with Durability of Effect. Ft Lauderdale, FL. Podium.

2024 American Society of Retina Specialists (ASRS) Annual Meeting (coauthor only), Real World Efficacy and Safety of Aflibercept 8 mg in Neovascular AMD. Stockholm, Sweden.

2023 American Society of Retina Specialists (ASRS) Annual Meeting, Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection 8 mg Versus 2 mg: A post Hoc Analysis of the Phase 2 CANDELA Study. July 2023. Seattle, WA

2023 Women in Ophthalmology Annual Meeting. Zeta-1 Phase 2 Trial- Efficacy and Safety of APX3330: A novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy. August 2023. Marco Island, FL

2022 American Society of Retina Specialists (ASRS) Annual Meeting, Infrared Imaging for the Evaluation of Complaints after Retinal Detachment Repair. July 2022. New York City, NY.

2019 Retina Society Annual Meeting (coauthor only), The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab, September 2018

2018 American Society of Retina Specialists Annual Meeting, A Rare Case of Bilateral Vision Loss, July 2018, Case-on-Demand

2016 Retina Society Annual Meeting, Efficacy of Ocriplasmin on Pharmacologic Full-Thickness Macular Hole Closure, September 2016

2015 Association for Research in Vision and Ophthalmology (ARVO), Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes, May 2015

2025 Outcomes of Suturing Superior Sclerotomies During Scleral Fixation IOL Surgery. Vail Vitrectomy. Abstract Accepted. Vail, Colorado February 2025

2025 Update on Biosimilar Therapeutics in Retinal Disease. Telling it Like it Is. Orlando FL. Feb 2025

2024 Update on Biosimilar Therapeutics in Retinal Disease. Masters of Ophthalmology Course. Orlando FL

2023 Using Multimodal Imaging to Help Make the Diagnosis. American Academy of Ophthalmology. Heidelberg Booth. Nov 2023.

2023 Update on Biosimilar Therapies. Masters of Ophthalmology Course. Orlando, FL.

2022 Update on Port Delivery System, Retina World Congress E-live. Oct 16, 2022

2019 Optimizing Cataract Surgery Outcomes in Patients with Concurrent Retinal Disease, Washington Retina Symposium, Tysons Corner, VA

2025 Speaker, Advances in Retina Meeting, Denver, Colorado

2023 Speaker, Advances in Retina Meeting, St. Louis, Missouri

2023 Moderator, Young MD Connect Meeting, American Academy of Ophthalmology, San Francisco, CA

2023 Moderator, Women In Retina Case Conference, American Society of Retina Specialists Annual Meeting, Seattle, WA

2023 Moderator, Surgical Symposium aSection, Vit-Buckle Society Annual Meeting, Las Vegas, Nevada

2022 Speaker, Advances in Retina Meeting, St. Louis, Missouri

2022 Panelist, ASRS Business of Retina Meeting, Virtual

2022 Moderator, Business of Retina Section, Vit-Buckle Society Annual Meeting, Las Vegas, Nevada

2021 Speaker, Advances in Retina Meeting, St. Louis, Missouri

2021 Moderator, Vit-Buckle Society Annual Meeting, Virtual

2020 Moderator, Vit-Buckle Society Annual Meeting, Virtual

2020 Moderator, Washington Retina Symposium, Virtual

2024 EURETINA (Audio Narrated Free Paper). Outcomes of Patients With Diabetic Macular Edema and Baseline Best-corrected Visual Acuity 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial. Barcelona, Spain

2024 Retina World Congress (E-poster). Outcomes of Patients With Diabetic Macular Edema and Baseline Best-corrected Visual Acuity 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial. Ft Lauderdale, FL.

2018 American Society of Retina Specialists Annual Meeting, Outer Retinal Abnormlities in “Poppers” Retinopathy as compared to Solar and Laser Induced Retinopathy, July 2018

2017 Retina Society Annual Meeting, Optical Coherence Tomography Angiography and Dark Adaptation in Screening of Hydroxychloroquine Toxicity, September 2017

2017 American Society of Retina Specialists Annual Meeting, Optical Coherence Tomography Angiography and Dark Adaptation in Screening of Hydroxychloroquine Toxicity, August 2017

2017 Association for Research in Vision and Ophthalmology (ARVO), Optical Coherence Tomography Angiography and Dark Adaptation in Screening of Hydroxychloroquine Toxicity, May 2017

2016 Association for Research in Vision and Ophthalmology (ARVO), Efficacy of Ocriplasmin on Pharmacologic Full-Thickness Macular Hole Closure, May 2016

2023 “Zeta-1 Phase 2 Trial Safety and Tolerability Results for APX3330: A Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy.

Women in Ophthalmology Summer Symposium, August 2023
2019 Atlantic Coast Retina Conference, Serous Retinal Detachment from Orbital Prostate Metastasis, January 2019

2018 Atlantic Coast Retina Conference, Choroidal Granuloma from Sarcoidosis, January 2018

2018 Boston Retina, Uveitis, and Imaging Network Meeting. Poppers Retinopathy. January 2018

2017 Wills Eye Conference, Optical Coherence Tomography Angiography and Dark Adaptation in Screening of Hydroxychloroquine Toxicity, March 2017

2016 Wills Eye Conference, Efficacy of Ocriplasmin on Pharmacologic Full-Thickness Macular Hole Closure, March 2016

2015 Wills Eye Conference, Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes, May 2016
2011 Wills Eye Tumor Conference, Fluorescein angiography of neoplastic cyclitic membrane in an eye with medulloepithelioma, July 2010
2011 Wills Eye Tumor Conference, A clinical survey of 3706 benign and malignant iris

2012 Sigma Xi Research Symposium, Effect of orbital steroid injections on intraocular pressure, April 2012

2012 Alpha Omega Alpha Research Symposium, Effect of orbital steroid injections on intraocular pressure, March 2012

2011 Alpha Omega Alpha Research Symposium, A clinical survey of 3706 benign and malignant iris lesions, March 2011

2011 Sigma Xi Research Symposium, A clinical survey of 3706 benign and malignant iris lesions, April 2011

2011 Jefferson Pathology Honors Program Student Research Symposium, Assessment of papillary thyroid carcinoma with BRAF V600E mutation, April 2011

2023 USF Ophthalmology Residents Teaching Conference, Update on Dry AMD

2020 Invited Guest. ASRS Crystal Apple Award. Virtual Lecture for Recipient Caroline Baumal.

2019 Georgetown Residency “Point-CounterPoint” Seminar

2018 Tufts New England Eye Center Grand Rounds, Cancer Associated Retinopathy

2017 Wills Eye Chiefs Rounds, Morgagnian Cataract

2017 Wills Eye Chiefs Rounds, Surgical Management of Complex Retina

2016 Wills Eye Chiefs Rounds, Cancer-Associated Retinopathy

2016 Wills Eye Chiefs Rounds, Intraorbital wooden foreign body

2016 Wills Eye Visiting Professor Rounds, Ocriplasmin and Full-Thickness Macular Hole

2016 Wills Eye Visiting Professor Rounds, Intraocular Foreign Body and Siderosis

2015 Wills Eye Chiefs Rounds, Pigment epithelial detachment

2015 Wills Eye Chiefs Rounds, Esthesioneuroblastoma

2014 Wills Eye Chiefs Rounds, Autoimmune Retinopathy

2014 Wills Eye Visiting Professor Rounds, Xanthogranuloma with Adult Onset Asthma

1. Sharma P. Contributor, Ocriplasmin Outcomes Study, Macula Society, 2015.

2. Sharma, P: Contributor, Eye and Dermatologic Findings in PowerPoint, Jefferson Clinical Images Database. Thomas Jefferson University, 2012.

3. Sharma, P. CMV Retinitis. Contributor. Eyewiki.aao.org/CMV_Retinitis

4. Vakharia, P. Healio Case Challenges, Faricimab Cases. 2023

5. Vakharia, P. Syfovre Expert Spotlight: Case Study Review. 2023

2024 Head to Head. American Academy of Ophthalmology Meeting 2024. Avelis. (Pending)

2024 New Hope for Geographic Atrophy: An Expert Discussion of Key Practice Changes. Paradigm Medical Communications

2024 There’s More to the Anti-VEGF Story: Practical Tips for Treating Patients with Neovascular AMD. Evolve Medical Education

2023 Overview of Biosimilar Therapeutics. Peer Direct Compendium

2023 DME/AMD Roundtable. AAO 2023. Bryn Mawr Communications

2023 DME/AMD Roundtable. ASRS 2023. Bryn Mawr Communications

2023 Beyond the Surface. Mastering Retinal Detachment from Diagnosis to Surgery. Omnicurious-CME Experts

2023: Overcoming Adherence Challenges in nAMD Exploring Variable Dosing Strategies and New Treatment Pathways and Delivery Systems. Ophthalmology 360 Virtual Summit Series.

2022 Geographic Atrophy in Modern Clinical Practice: Examining Diagnosis, Prognosis, and the Therapeutic Pipeline. Evolve 2022.

2022 Geographic Atrophy: Monitoring Disease Progression and Emerging Therapies. Issue 4. Healio/Vindico 2022.

2022 KOL Knockout; Retina Edition- Treatment Outcomes to Vie For- Round 1. Evolve 2022.

https://evolvemeded.com/course/2235_Round_1_Enduring?page=1
2022 KOL Knockout; Retina Edition- Treatment Outcomes to Vie For- Round 2. Evolve 2022. Live at AAO 2022.

2021 Managing the Diabetic Eye: Real-World Strategies for Improving Compliance and Visual Outcomes. Evolve 2021. https://www.evolvemeded.com/course/2124-supp?page=1

New Retina Radio Journal Club: Duration of Macular Detachment and Final Visual Prognosis. March 2023. https://eyetube.net/series/new-retina-radio-journal-club/new-retina-radio-journal-club-duration-of-macular-detachment-and-final-visual-prognosis

Straight from the Cutter’s Mouth: Episode 419. February 2024. Journal Club Discussion Including Ocular Adverse Events after Faricimab Injections, Rate of Retinal Detachment after Cataract Surgery, Syfovre Debate for Dry AMD. https://www.retinapodcast.com/episodes/2024/2/5/episode-419-journal-club-discussion-including-ocular-adverse-events-after-faricimab-injections-rate-of-retinal-redetachment-after-cataract-surgery-syfovre-debate-for-dry-amd

Straight from the Cutter’s Mouth: Episode 419. December 2023. Journal Club on Real-World Results of Faricimab, AI Prediction for Dry AMD, Risk of Stroke/MI after Retinal Arteriole Occlusion, Climate Change. https://www.retinapodcast.com/episodes/2023/12/6/episode-414-journal-club-on-real-world-results-of-faricimab-ai-prediction-for-dry-amd-risk-of-strokemi-after-retinal-arteriole-occlusion-climate-change

Straight from the Cutter’s Mouth: Episode 401. August 2023. ASRS 2023 Annual Meeting Thoughts and Impressions Including Dry AMD Pharmacotherapy Discussion. https://www.retinapodcast.com/episodes/2023/8/8/episode-401-asrs-2023-annual-meeting-thoughts-and-impressions-including-dry-amd-pharmacotherapy-discussion

Straight from the Cutter’s Mouth: Episode 398. July 2023Journal Club Including Fluorescein Angiography Cost, Biosimilar Effect on Health Care Syste Cost, Practice Consolidation in Ophthalmology, Physician Turnover in Ophthalmology. https://www.retinapodcast.com/episodes/2023/7/12/episode-398-journal-club-including-fluorescein-angiography-cost-biosimilar-effect-on-health-care-system-cost-practice-consolidation-in-ophthalmology-physician-turnover-in-ophthalmology

Straight from the Cutter’s Mouth: July 2023. Mini-Pod Breaking News: Syfovre Adverse Events. https://www.retinapodcast.com/episodes/2023/7/20/mini-pod-breaking-news-syfovre-adverse-events

Straight from the Cutter’s Mouth: Episode 393. June 2023 Retinal Physician Preview, Oncology and Uveitis Discussion. http://www.retinapodcast.com/episodes/2023/5/31/episode-393-june-2023-retinal-physician-preview-oncology-and-uveitis-discussion

Straight from the Cutter’s Mouth: Episode 385. April 2023 Retinal Physician Preview, Incorporating Intravitreal Injections for Geographic Atrophy into Retina Practices. Straight from the Cutter’s Mouth: Episode 393. June 2023 Retinal Physician Preview, Oncology and Uveitis Discussion. http://www.retinapodcast.com/episodes/2023/5/31/episode-393-june-2023-retinal-physician-preview-oncology-and-uveitis-discussion

Straight from the Cutter’s Mouth: Episode 381. March 2023 Retinal Physician Discussion Focusing on Gene Therapy and Optogenetics. http://www.retinapodcast.com/episodes/2023/3/8/episode-381-march-2023-retinal-physician-discussion-focusing-on-gene-therapy-and-optogenetics

Straight from the Cutter’s Mouth: Episode 368. Journal Club Discussion on Private Equity and Healthcare Expenditures, Pediatric Retinal Detachment, Management of Asymptomatic Retinal Detachments, Gender Trends in Authorship. http://www.retinapodcast.com/episodes/2022/11/13/episode-368-journal-club-discussion-on-private-equity-and-healthcare-expenditures-pediatric-retinal-detachment-management-of-asymptomatic-retinal-detachments-gender-trends-in-authorship

New Retina Radio Journal Club: PIC-Like Reactions in Unrelated Retinal Diseases. Dec 2022. https://eyetube.net/series/new-retina-radio-journal-club/new-retina-radio-journal-club-profiling-punctate-inner-choroidopathy-like-reactions

New Retina Radio Journal Club: Update on Biosimilars. Nov 2022. https://eyetube.net/series/new-retina-radio-journal-club/biosimilars-in-retina-a-pair-of-phase-3-papers

Straight from the Cutter’s Mouth: Episode 366. Nov 2022 Retinal Physician Discussion Focusing on Future of Retina Clinic, Diabetic Automated Screening, Macular Degeneration Management and Controversies. http://www.retinapodcast.com/episodes/2022/10/30/episode-366-november-2022-retinal-physician-discussion-focusing-on-future-of-retina-clinic-diabetic-automated-screening-macular-degeneration-management-and-controversies

New Retina Radio Journal Club: Update on Coding/Billing. May 2022. https://eyetube.net/podcasts/new-retina-radio/tags/journal-club/new-retina-radio-journal-club-trends-in-retina-reimbursement

New Retina Radio Journal Club: PPV vs PnR for RRD. March 2022. http://eyetu.be/lanenezixe

Straight from the Cutter’s Mouth: Episode 358: September 2022 Retinal Physician Discussion Focusing on Diabetic Retinopathy with Drs. Nicholas Farber, Akshay Thomas, and Priya Vakharia. http://www.retinapodcast.com/episodes/2022/9/1/episode-358-september-2022-retinal-physician-discussion-focusing-on-diabetic-retinopathy-with-drs-nicholas-farber-akshay-thomas-and-priya-vakharia

Straight from the Cutter’s Mouth: Episode 354: August 2022 Retinal Physician Discussion focusing on Suprachoroidal Therapy with Dr. Priya Vakharia and Dr. Katherine Talcott. http://www.retinapodcast.com/episodes/2022/8/4/episode-354-august-2022-retinal-physician-discussion-focusing-on-suprachoroidal-therapy-with-dr-priya-vakharia-and-dr-katherine-talcott

Straight from the Cutter’s Mouth: Episode 339: Journal Club Discussion of Outcomes after Retinectomy for Proliferative Vitreoretinopathy, Gender Influence on Peer Review Process, and Diabetic Macular Edema. http://www.retinapodcast.com/episodes/2022/4/14/episode-339-journal-club-discussion-of-outcomes-after-retinectomy-for-proliferative-vitreoretinopathy-gender-influence-on-peer-review-process-and-diabetic-macular-edema-

Straight from the Cutter’s Mouth: Episode 335: Journal Club with Drs. Matthew Cunningham Geeta Lalwani, Lisa Olmos de Koo, and Priya Vakharia. http://www.retinapodcast.com/episodes/2022/3/9/episode-335journal-club-with-drs-matthew-cunningham-geeta-lalwani-lisa-olmos-de-koo-and-priya-vakharia

Straight from the Cutter’s Mouth: Episode 321: Retina Patient Case Scenarios Part Three, Secondary Intraocular Lens Surgery. http://www.retinapodcast.com/episodes/2021/11/22/episode-321-retina-patient-case-scenarios-part-three-secondary-intraocular-lens-surgery

Straight from the Cutter’s Mouth: Episode 314: October 2021 Retinal Physician Including Discussion of Diabetic Retinopathy, Trials, Focal Laser, and Crunch Effect of Anti-VEGF. http://www.retinapodcast.com/episodes/2021/9/30/episode-314-october-2021-retinal-physician-including-discussion-of-diabetic-retinopathy-trials-focal-laser-and-crunch-effect-of-anti-vegf

Straight from the Cutter’s Mouth: Episode 304: Retina Patient Case Scenarios Part 1: Macular Peeling http://www.retinapodcast.com/episodes/2021/7/26/episode-304-retina-patient-case-scenarios-part-one-macular-peeling

Straight from the Cutter’s Mouth: Episode 301: Retinal Physician Previous Including Discussion of Oversight of Vitreoretinal Fellowships, Diversity and Ophthalmology Residency Training, Incorporating New Tools in OR. http://www.retinapodcast.com/episodes/2021/7/7/episode-301-july-2021-retinal-physician-preview-including-discussion-of-oversight-of-vitreoretinal-fellowships-diversity-and-ophthalmology-residency-training-incorporating-new-tools-in-or

Straight from the Cutter’s Mouth: Episode 299: Journal Club Including Discussion of Persistent Opioid Use after Ophthalmic Surgery, Disparities in Clinical Trial Recruitment, and Telehealth COVID-19 Experience. http://www.retinapodcast.com/episodes/2021/6/20/epi-299-journal-club-including-discussion-of-persistent-opioid-use-after-ophthalmic-surgery-racial-disparities-in-clinical-trial-recruitment-and-telehealth-covid-19-experience

Straight from the Cutter’s Mouth: Episode 284: Journal Club Including Discussion of Metformin Association with AMD Risk, Bariatric Surgery Impact on Diabetic Retinopathy, and more. http://www.retinapodcast.com/episodes/2021/3/8/episode-284-journal-club-including-discussion-of-metformin-association-with-amd-risk-bariatric-surgery-impact-on-diabetic-retinopathy-and-more

Straight from the Cutter’s Mouth: Episode 272: Journal Club COVID-19 Retinal Detachment Presentation, Racial and Socioeconomic Disparities in Visual Impairment, Hormone Therapy Associate with RVO, Ranibizumab Biosimilar. http://www.retinapodcast.com/episodes/2020/12/20/episode-272-journal-club-covid-19-retinal-detachment-presentation-racial-and-socioeconomic-disparities-in-visual-impairment-hormone-therapy-association-with-rvo-ranibizumab-biosimilar

Straight from the Cutter’s Mouth: Episode 265: Journal Club Covering COVID-19 Related Studies, including protective value of slit lamp shields and glasses. http://www.retinapodcast.com/episodes/2020/11/9/episode-265-journal-club-covering-covid-19-related-studies-including-protective-value-of-slit-lamp-shields-and-glasses

Straight from the Cutter’s Mouth: Episode 259: Journal Club Including Discussion of COVID-19 Practice Responsiveness, Risk of Systemic Adverse Events with Anti-VEGF, and more. http://www.retinapodcast.com/episodes/2020/9/28/episode-259-journal-club-including-discussion-of-covid-19-practice-responsiveness-risk-of-systemic-adverse-events-with-anti-vegf-and-more

Straight from the Cutter’s Mouth: Episode 254: Journal Club Discussion of PIVOT Trial Quality of Life, Gender Differences in Retinal Detachment Repair, Artificial Intelligence Identification of Subretinal Fluid, and more. http://www.retinapodcast.com/episodes/2020/8/24/episode-254-journal-club-discussion-of-pivot-trial-quality-of-life-gender-differences-in-retinal-detachment-repair-artificial-intelligence-identification-of-subretinal-fluid-and-more

Straight from the Cutter’s Mouth: Episode 244: July/August 2020 Retinal Physician Preview: Discussion of Shaving During Vitrectomy, Low Vision Devices, Retinal Vein Occlusion, and Telemedicine. http://www.retinapodcast.com/episodes/2020/7/6/episode-244-julyaugust-2020-retinal-physician-preview-with-drs-priya-vakharia-and-shriji-patel-discussion-of-shaving-during-vitrectomy-low-vision-devices-retinal-vein-occlusion-telemedicine

Straight from the Cutter’s Mouth: Episode 239: Journal Club on Face-Down Positioning for Macular Holes and More. http://www.retinapodcast.com/episodes/2020/6/8/episode-239-journal-club-with-dr-priya-vakharia-and-dr-yoshihiro-yonekawa-including-discussion-of-face-down-positioning-for-macular-holes-and-more

Straight from the Cutter’s Mouth: Episode 225: Journal Club on CATT Trial Adherence, Protocol S 5 Year Visual Field Outcomes, and Gender Representation on the Podium In Ophthalmology http://www.retinapodcast.com/episodes/2020/4/8/episode-225-journal-club-with-dr-priya-sharma-vakharia-and-dr-will-parke

Straight from the Cutter’s Mouth: Episode 210: Discussion of Viral Medicine Article. Keep Insulting Doctors and Good Luck Finding a Physician in 10 Years. http://www.retinapodcast.com/episodes/2020/1/23/episode-210-discussion-of-viral-medical-article-keep-insulting-doctors-and-good-luck-finding-a-physician-in-10-years

Straight from the Cutter’s Mouth: Episode 209: Journal Club on Timing of Retinal Detachment Surgery, Cost of Post-Cataract Surgery Topical Drops, Removal of Anterior Chamber Retained Lens Material, and more. http://www.retinapodcast.com/episodes/2020/1/15/episode-209-journal-club-on-timing-of-retinal-detachment-surgery-cost-of-post-cataract-surgery-topical-drops-removal-of-anterior-chamber-retained-lens-material-and-more

Straight from the Cutter’s Mouth: Episode 204: Journal Club Featuring AMD Cost Analysis, DME Real-World Trends, PVDs and Retinal Breaks. http://www.retinapodcast.com/episodes/2019/12/10/episode-204-journal-club-featuring-amd-cost-analysis-dme-real-world-trends-pvds-and-retinal-breaks

Straight from the Cutter’s Mouth: Episode 198: Journal Club about Online Physician Reviews, Systematic Review Reliability, SCORE2 24 month Data, Brolucizumab FDA Approval. http://www.retinapodcast.com/episodes/2019/11/1/dr3n6dzy9wbctrsgxnmwxrl8lx7d5g

Straight from the Cutter’s Mouth: Episode 193: Journal Club Discussing the LEAVO RVO study, Endophthalmitis after Cataract Surgery IRIS Registry study, PRP in RISE/RIDE, Online Conent for Diabetic Retinopathy. http://www.retinapodcast.com/episodes/2019/9/29/episode-193-journal-club-discussing-the-leavo-rvo-study-endophthalmitis-after-cataract-surgery-iris-registry-study-prp-in-riseride-online-content-for-diabetic-retinopathy

Straight from the Cutter’s Mouth: Episode 187: Journal Club. Gender Disparities, Informed Consent in Resident Cataract Surgery, Gene Therapy, and Surgical Errors. http://www.retinapodcast.com/episodes/2019/8/25/episode-187-journal-club-gender-disparities-informed-consent-in-resident-cataract-surgery-gene-therapy-and-surgical-errors

Straight from the Cutter’s Mouth: Episode 14: Retina Fellowship Applications Match Panel. http://www.retinapodcast.com/episodes/2016/12/22/episode-14-retina-fellowship-applications-match-panel

Wills Eye Innovation Grant Shields Carol (PI) 2015-2016
Qualitative and quantitative analysis of superficial and deep capillary density using optical coherence tomography angiography in normal and irradiated eyes

Wills Eye Innovation Grant Affel Libba (PI) 2015-2016
AdaptDx Dark Adaptation and Hydroxychloroquine Retinal Toxicity Screening.

ONL Therapeutics 1204-RRD-002 Study- A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects with Macula-off Rhegmatogenous Retinal Detachment

Recens Medical- COOL3S study- A randomized, Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia as Local Anesthesia for Patients Receiving Intravitreal Injection

Regeneron VGFTe-HD-OD-2444- A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants with Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema.

APEX – X82-OPH-201 entitled “A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea® compared to prn Eylea® monotherapy in neovascular AMD (Tyrogenex). 2017

CAPELLA – R2176-3-AMD-1417- A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration (Regeneron). 2017

CHROMA – A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Assess The Efficacy And Safety Of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration (Genentech). 2017-2018

FILLY – POT-CP121614- A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA) (Apellis). 2017-2019

HEMERA – A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2CAGsCD59 in Patients with Advanced Non Exudative (Dry) Age-Related Macular Degeneration with Geographic Atrophy (Hemera Biosciences). 2017-2019

OMASPECT – GX30191- A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of Lampalizumab In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration Who Have Completed A Roche-Sponsored Study (Genentech). 2017.

ONYX – REGN910-3-AMD-1517 – A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age Related Macular Degeneration (Regeneron). 2017

PANORAMA – VGFTe-OD-1411- A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (Regeneron). 2017-2019

PRELUDE – CNTO2476MDG2002 – A Phase 2b, multicenter, double-masked, randomized study evaluating the safety and clinical response of sub-retinal administration of CNTO 2476 in subjects with visual acuity impairment associated with Geographic Atrophy Second (Janssen). 2017

PRO-CON – VGFTe-AMD-1507- A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) versus Sham as Prophylaxis against Conversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes (Regeneron). 2017-2019

REGENXBIO- A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate theSafety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD) (Regenexbio). 2017-2019.

RUBY- REGN910-3-DME-1518 – A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema (Regeneron). 2017

TLC- TLC399A2002 – A Phase IIa Trial of TLC399 (ProDex) in Subjects with Macular Edema due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability (TLC). 2017

COOL-3: A Randomized, Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia as Local Anesthesia for Patients Receiving Intravitreal Injections.2021-present.

Genentech GR40549 PORTAL: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patient with Neovascular Age-Related Macular Degeneration. 2021-Present.

Kodiak KSI-CL-101: A Phase 1/1b Open Label, Multi-Center Exploratory Study to Investigate
the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single
and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age Related Macular
Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion.
2021-Present.

Ionis 696844-CS5 GOLDEN: A Phase 2, Randomized, Placebo-Controlled, Double-Masked
Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor
of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related
Macular Degeneration, 2021-Present.

Genentech GR40973 GALLEGO: A Phase II, Multicenter, Randomized, Single-Masked,
Sham−Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of
FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular
Degeneration. 2021-Present.

Genentech BP40899 DOVETAIL: A Multi-Center, Non-Randomized, Open-Label, Multiple
Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and
Pharmacodynamics of RO7200220 in Monotherapy and in Combination with Ranibizumab
following Intravitreal Administration in Patients with Diabetic Macular Edema.
2021-Present.

Kodiak KSI-CL-102: A Phase 2, Prospective, Randomized, Double-masked, Active Comparator
Controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal
Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular
Degeneration. 2021-Present.

Genentech GR40550 PAGODA: A Phase III, Multicenter, Randomized, Visual
Assessor-Masked, Active Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the
Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema.
2021-Present.

Genentech BP41321 CANBERRA: A Randomized, Double-Masked 48-Week, Parallel-Group,
Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in
Patients with Diabetes Mellitus Type 1 or Type 2 with Treatment-naïve Diabetic Retinopathy.
2021-Present.

Gyroscope GT005-02 EXPLORE: A Phase 2, Outcomes Assessor-Masked, Multicentre,
Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as
a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-Related
Macular Degeneration. 2021-Present.

Bayer 20968 PULSAR: A Randomized, Double-Masked, Active-Controlled, Phase 3 Study of
the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related
Macular Degeneration. 2021-Present.

IVERIC Bio ISEE2008 GATHER2: A Phase 3 Multicenter, Randomized, Double-Masked,
Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of
Zimura™ (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry
Age-Related Macular Degeneration. 2021-Present.

NGM621-GA-201 CATALINA: A Phase 2 Multicenter, Randomized, Double-Masked,
Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in
Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular.
2021-Present

DETeR: Investigator Initiated Study of the Effect on Pain and Inflammation with DEXTENZA
Treatment in Patients Undergoing Routine Intravitreal Anti-VEGF Injections.
2021-Present.

Genentech-Roche GR41987 RHONE-X: A Multicenter, Open-Label Extension Study to Evaluate
the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema.
2021-Present

Regeneron VGFTe-HD-DME-1934 PHOTON: A Randomized, Double-Masked,
Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in
Patients with Diabetic Macular Edema. 2021-Present.

Genentech-Roche BP41670: A Two-Part, Phase I Study to Investigate the Safety, Tolerability,
and Pharmacokinetics of RO7250284 following Intravitreal Administration of Unmasked Multiple
Ascending Doses and Masked Sustained Delivery from the Port Delivery System in Patients
with Neovascular Age-Related Macular Degeneration. 2021-Present.

AsclepiX AXT107-CS101 CONGO: A Phase 1/2a Study of the Safety and Bioactivity of AXT107
in Subjects with Diabetic Macular Edema. 2021-Present.

AsclepiX AXT107-CS102 SHASTA: A Phase 1/2a Study of the Safety and Bioactivity of AXT107
in Subjects with Neovascular Age-Related Macular Degeneration.
2021-Present.

Genentech-Roche GR42558 GALLAGOLE: A Multicenter, Open-Label Extension Study to
Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients
with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
2021-Present.

Opthea OPT-302-1005 COAST: A Phase 3, Multicentre, Double-masked, Randomised Study to
Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept,
Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular
Degeneration (nAMD). 2021-Present.

Kodiak KS301P107 DAYLIGHT: A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and
Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with
Neovascular (Wet) Age-related Macular Degeneration (wAMD).
2021-Present.

Kodiak KS301P107 GLIMMER: A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and
Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual
Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
2021-Present.

Gyroscope GT005-03 HORIZON: A Phase II, Open-Label, Outcomes-Assessor Masked,
Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of
GT005 Administered as a Single Subretinal Injections in Subjects with Geographic Atrophy
Secondary to Dry Age-Related Macular Degeneration. 2021-Present.

Genentech-Roche GR42691 AVONELLE-X: A Multicenter, Open-Label Extension Study to
Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Neovascular
Age-Related Macular Degeneration. 2021-Present.

Genentech-Roche GR41986 COMINO: A Phase III, Multicenter, Randomized, Double-Masked
Active Comparator Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients
with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion. 2021-Present.

Genentech-Roche GR41984 BALATON: A Phase III, Multicenter, Randomized, Double-Masked,
Active Comparator Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients
with Macular Edema Secondary to Branch Retinal Vein Occlusion. 2021-Present.

Eyepoint EYP1901-001: A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation
Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects with Wet AMD. 2021-Present.

Annexon ANX007-GA-01 ARCHER: A Phase 2, Multicenter, Randomized, Parallel-Group,
Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of
ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA)
Secondary to Age-Related Macular Degeneration (AMD). 2021-Present.

GT005-01 Gyroscope Therapeutics FOCUS Study
An Open Label First In Human Phase I/II Multicentre Study To Evaluate The Safety, Dose Response And Efficacy Of GT005 Administered As A Single Subretinal Injection In Subjects With Macular Atrophy Due To Age-Related Macular Degeneration

ML43000 BELVDERE Study
A Phase IV, Multicenter, Open-Label, Single-Arm Study of the Response to Treatment After Transition to the Port Delivery System with Ranibizumab (SUSVIMO™ [Ranibizumab Injection]) in Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Intravitreal Agents Other than Ranibizumab

OTX-TKI-2020-01 Ocular Therapeutics Inc Study
A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for lntravitreal Use in Subjects with Neovascular Age-Related Macular Degeneration

Unity Biotechnology Inc UBX1325-01 Study
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age­Related Macular Degeneration

BP43445 Alluvium Study
A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Diabetic Macular Edema

4D-150-C001 4DMT Study
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-I 50 Gene Therapy in Adults with Neovascular Age-Related Macular Degeneration

RGX-314-2104 ATMOSPHERE Study
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

RGX-314-2103 Study
A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered via Subretinal Delivery in Participants with Neovascular Age-related Macular Degeneration

ALXN2040-201 Alexion Study
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

EYP-1901-201 DAVIO 2 Study
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

OTT-166-201 DREAM Study
A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT 166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)

Novartis CLNP023E12201 Study
A randomized, participant and investigator masked, placebo-controlled, multicenter, proof-of-concept study to assess the safety and efficacy of LNP023 (lptacopan) in patients with early and intermediate age-related macular degeneration
Allgenesis AG-73305 study –  A multicenter, open-labeled, phase 2a study evaluating the safety, tolerability, and efficacy of intravitreal AG-73305 in patients with diabetic macular edema
Aviceda AVD-104 – A Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants with Geographic Atrophy Secondary to Age-related Macular Degeneration
Regeneron Quasar – Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Genentech-Roche BP43464 – A Phase II, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ro7200220 in combination with ranibizumab administered intravitreally in patients with diabetic macular edema
Genentech-Roche CR44823 – A comparative study between standard early treatment of diabetic retinopathy study (setdrs) and electronic etdrs for best corrected visual acuity testing
Genentech-Roche GR44277 –  A Phase III, multicenter, randomized, double‑masked, sham‑controlled study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ro7200220 administered intravitreally in patients with uveitic macular edema
Novartis GT-Oracle – A long-term follow-up study to evaluate the safety and durability of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored antecedent study
Ionis – A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

JANSSEN JNJ-81201887 – A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD

OPHTHEA Shore OPT-302 – A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD).
Regenxbio RGX-314-3101 – A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Regenxbio RGX-314-5101 – A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
Unity ENVISION UBX1325-03- A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration
Unity ASPIRE UBX1325-04 – A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema

Eyepoint EYP-1901-302- A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

Eyebiotech Limited EYE-RES-102 Study
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal Ranibizumab(0.5mg) in Participants with Diabetic Macular Edema

Stealth Biotherapeutics SPIAM-301 ReNEW Study
A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to
Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of
Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (Dry AMD)

ANX007-GA-02 Archer II Study
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients with Geographic Atrophy (GA)

Priovant Therapuetics PVT-2201-303 Clarity Study
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-,Posterior-, and Panuveitis

ISEE2009 Gather II Study
An Open-Label Extension (Ole) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with GeographicAtrophy who Previously Completed Phase 3 Study ISEE2008

OTX-TKI-2023-AMD-303 SOL R Study
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects withNeovascular Age- Related Macular Degeneration

Kyowa Kirin 4951-002 Study
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor ReceptorInhibitor, in Patients with Neovascular Age-Related Macular Degeneration

Kyowa Kirin 4951-003 Study
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor ReceptorInhibitor, in Patients with Diabetic Macular Edema

81201887NAP0001 Study
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants

BP44241 Rivoli Study
A Phase Ib, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Biological Activity, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200394 in Participants with Macular Edema Secondary to Central Retinal Vein Occlusion

Kyoto GION Study
A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central RetinalArtery Occlusion (CRAO)

OTX-TKI-2023-AMD-301 SOL 1 Study
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects withNeovascular Age-Related Macular Degeneration

4DMT 4D-150-C002 Spectra Study
A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults with Diabetic Macular Edema

Alcon RTE888-E001 NOVA-1 Study
A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 SustainedRelease Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration

Retina Times, “Relationship Advice” Section Editor, 2020-presen

ASRS Film Festival Judge, ASRS 2020, Virtual Meeting

Reporter for Retina Times, ASRS 2023, Seattle WA

Reporter for Retina Times, ASRS 2019, Chicago, Illinois

Reporter for Retina Times, ASRS 2018, Vancouver, Canada

Ophthalmology Management Editorial Board

Ophthalmology 360 Editorial Board

2022-2025: Journal of Vitreoretinal Disease

2022: BMJ Open Ophthalmology

2022: Retina

2025-current President, Tampa Bay Ophthalmology Society

2025-current Co-Chair of Sunshine Eye Meeting

2024-current Coeditor for Current Opinion in Ophthalmology, Controversies Section

2024-current Early Career Section Co-Chair, American Society of Retina Specialists

2024-current Executive Committee, Vit-Buckle Society

2023-current “Member at Large”- Florida Society of Ophthalmology

2020-2023 Website/Social Media Committee, Vit-Buckle Society

2019-2021 Maryland Society of Eye Physicians and Surgeons, Social Media Committee Chair

2019-2021 Fellowship Committee, Retina Group of Washington

2019-2021 Marketing Committee, Retina Group of Washington

2024 Journal of Vitreoretinal Diseases- Distinguished Contributor Award

2024 Keynote Speaker: Sankara Eye Foundation Gala, Tampa, FL

2023 Women in Retina Clinical Trial Incubator Program

2023 Joanne Angle Abstract of Distinction- Women in Ophthalmology
Annual Meeting (Top Abstract)

2023 Tampa Magazine Top Doc

2022 Ophthalmology Management “Top 40 under 40” doctor

2022 Castle Connelly Top Doctor- “Rising Star”

2022 Florida Top Doctor

2022 Vit-Buckle Society “Best Moderator” Award

2020 Baltimore Top Doctor

2019 Oral Presentation Award, Atlantic Coast Retina Conference, Boston, MA

2016-2017 Chief Resident, Wills Eye Hospital

2016 James Shipman Award, Excellence in Research, Philadelphia, PA

2016 Heed Ophthalmic Foundation Residents Retreat

2016 Teamwork Badge: Jefferson Cheers for Peers

2013 Honorable Mention: Carroll R. Mullen Memorial Prize in Ophthalmology

2012-13 Junior AOA (Alpha Omega Alpha) Honor Society

2012-13 George McClellan Surgical Honor Society Membership

2011 Sigma Xi Research Symposium Award

2011 -13 Hobart Amory Hare Medical Honor Society Membership

2009 President’s Sparks Award (4.0 Cumulative GPA)

2008 President’s Freshman Award (4.0 Cumulative GPA)

2011- Clean Water Trip, Guyana, South America

2017- Cataract Mission Trip, Belize, Central America

2019- Retinal Surgical Mission Trip, Accra, Ghana, Africa

2021-present Florida Medical License

2019-2021 Maryland Medical License

2019-2021 DC Medical License

2019-2021 Virginia Medical License

2017-2019 Massachusetts Medical License

2019-present Board Certification, American Board of Ophthalmology

2024-present Collaborative Assistant Professor, University of South Florida, Morsani College of Medicine

2019-2020 Clinical Instructor, Washington Hospital Center

2017-2019 Clinical Associate, Ophthalmology, Tufts Medical Center

2016-2017 Co-Chief Resident, Wills Eye Hospital

2018-2019 Boston Imaging Reading Center, Junior Reader

2021-ongoing HCA Northside Hospital St. Petersburg, FL

2019-2021 Anne Arundel Medical Center Annapolis, MD

2019-2021 Inova Fair Oaks Medical Center Fairfax, VA

2019-2021 Washington Hospital Medical Center Washington, DC

2017- 2019 Tufts Medical Center Boston, MA

2021-present Member, Florida Society of Ophthalmology

2021-present Member, Tampa Bay Ophthalmology Society

2019-present Member, Vit-Buckle Society

2015-present Member, American Academy of Ophthalmology

2017-present Member, American Society of Retina Specialists

2017-2019 Member, SEE International

2009-2021 Member, American Medical Association

2019-2021 Member, Maryland Society of Eye Physicians and Surgeons

2019-2021 Member, Washington DC Metropolitan Ophthalmology Society

2017-2019 Member, Massachusetts Society of Eye Physicians and Surgeons

2017-2019 Member, Boston Retina, Uveitis, and Imaging Network

2016-2017 Professional Education Committee, Wills Eye Hospital

2016-2017 Patient Safety Committee, Wills Eye Hospital

2015-2017 Member, Pennsylvania Academy of Ophthalmology

Spinning

Hiking

Traveling